OBI Pharma Inc (浩鼎生技) has signed an agreement with Odeon Therapeutics (Hong Kong) Ltd (康騰浩諾香港生物科技) to give it the rights to two of its experimental drugs, OBI-833 and OBI-999, in China, OBI said on Tuesday.
OBI would receive US$200 million for the licensing of the cancer drugs, which includes US$12 million in newly issued Odeon shares as a signing payment, and US$188 million as development and commercialization milestone payments, the Taipei-based company said in a regulatory filing.
The drug developer would also receive double-digit percentage royalties on Odeon’s net sales of the two drugs after they are approved in China, it said.
Photo: Chen Yung-chi, Taipei Times
OBI granted Odeon exclusive rights to further develop, register and commercialize OBI-999 and OBI-833, it said, adding that the deal also includes Hong Kong and Macau.
Odeon would be responsible for all development costs, as well as subsequent regulatory and commercialization costs, it added.
The Ministry of Economic Affairs’ Investment Commission has approved the deal, OBI said.
As China’s cancer treatment market has great potential for growth, OBI and Odeon are planning to press ahead with the research and sale of the two drugs, aiming to share the commercial benefits, the filing said.
OBI-833 and OBI-999 are experimental drugs targeting Globo H, a tumor antigen that has been detected in up to 15 different cancers and has been reported to play an important role in tumor progression.
OBI-833 is a therapeutic cancer vaccine consisting of a synthetic Globo H antigen, while OBI-999 is a novel antibody drug conjugate using a Globo H antibody to target cancer cells with high Globo H expression.
“Odeon looks forward to working closely with OBI to bring these new treatment options to patients in China,” OBI chief executive officer Tim Xiao (肖汀) said in a statement.
OBI-999 has completed phase 1 trials in the US, showing excellent safety and pharmacokinetics, while OBI-333 also demonstrated great potential as an immune-oncology therapeutic vaccine, Xiao said.
OBI said that it gained local approval to conduct phase 2 clinical trial for OBI-333, expecting primary endpoint evaluation in 2024.
DAMAGE REPORT: Global central banks are assessing war-driven inflation risks as the law of unintended consequences careens around the world, spiking oil prices Central banks from Washington to London and from Jakarta to Taipei are about to make their first assessments of economic damage after more than two weeks of conflict between the US and Iran. Decisions this week encompassing every member of the G7 and eight of the world’s 10 most-traded currency jurisdictions are likely to confirm to investors that the specter of a new inflation shock is already worrying enough to prompt heightened caution. The US Federal Reserve is widely expected to do exactly what everyone anticipated weeks ahead of its March 17-18 policy gathering: hold rates steady. The narrative surrounding that
At a massive shipyard in North Vancouver, Canadian workers grind metal beams for a powerful new icebreaker crucial to cementing the country’s presence in the increasingly contested arctic. Icebreakers are specialized, expensive vessels able to navigate in the frozen far north. And “this is the crown jewel,” said Eddie Schehr, vice president of production at the Seaspan shipyard. For Canadian Prime Minister Mark Carney, who heads to Norway next Friday to observe arctic defense drills involving troops from 14 NATO states, Canada’s extreme north has emerged as a strategic priority. “Canada is and forever will be an Arctic nation,” he said ahead of
Chinese entrepreneur Frank Gao used to spend long hours running his social media accounts but now outsources the chore to artificial intelligence (AI) agent tool OpenClaw, which is taking China by storm despite official warnings over cybersecurity. OpenClaw, created in November by an Austrian coder, differs from bots such as ChatGPT because it can execute real-life tasks such as sending e-mails, organizing files or even booking flight tickets. “Since January, I’ve spent hours on the lobster every day,” Gao said in an interview, referring to OpenClaw’s red crustacean mascot. “We’re family.” After downloading OpenClaw, users connect it to artificial intelligence models of their
PRICE HIKES: The war in the Middle East would not significantly disrupt supply in the short term, but semiconductor companies are facing price surges for materials Taiwan’s semiconductor companies are not facing imminent supply disruptions of essential chemicals or raw materials due to the war in the Middle East, but surges in material costs loom large, industry association SEMI Taiwan said yesterday. The association’s comments came amid growing concerns that supplies of helium and other key raw materials used in semiconductor production could become a choke point after Qatar shut down its liquefied natural gas (LNG) production and helium output earlier this month due to the conflict. Qatar is the second-largest LNG supplier in the world and accounts for about 33 percent of global helium output. Helium is
RSS